The final portion of the program shifts to case-based discussion, with the panel applying earlier debates to real-world clinical scenarios in relapsed/refractory DLBCL. The first case, a fit 58-year-old with early relapse, prompts consensus around rapid movement to CAR-T therapy with bridging strategies such as polatuzumab-based regimens, whereas the second case highlights challenges related to primary refractory disease and inconsistent caregiver support. The program concludes with closing remarks and a debate winner announcement, reinforcing the collaborative nature of evolving treatment strategies in LBCL.
